Ir directamente a la navegación principal Ir directamente a la búsqueda Ir directamente al contenido principal

SARS-Cov-2 Infection and Seroconversion Rates in Healthcare Providers Prior to COVID-19 Vaccine Rollout

  • Sanghyuk S. Shin
  • , Miriam Bender
  • , Delphine C. Malherbe
  • , Hannah Vasquez
  • , Brianna M. Doratt
  • , Ilhem Messaoudi

Producción científica: Articlerevisión exhaustiva

Resumen

Objective: A 6-month longitudinal surveillance study of asymptomatic healthcare providers (HCP) was carried out at a large urban academic medical center in the United States to assess whether their job occupation with higher exposure risks to SARS-CoV-2 would equate with higher risk of contracting COVID-19 at the beginning of the pandemic before COVID-19 vaccines were available. Methods: A longitudinal cohort study design was used to collect and analyze immunological and virological monitoring data and self-report survey assessments of personal protective equipment (PPE) availability, adherence to infection control guidelines, and time spent on COVID-19 wards. Results: Among 289 eligible participants, SARS-CoV-2 exposure risk was high with 48–69% participants working in COVID-19 units and more than 30% of them caring for COVID-19 patients. However, the seroconversion rate was low with only 2.1% of participants developing humoral or cellular immunity against SARS-CoV-2. Conclusion: Our study findings suggest that, for this HCP cohort working at a large urban academic medical center, a low incidence of SARS-CoV-2 infection could be maintained under conditions of strict infection prevention protocols and reliable PPE availability.

Idioma originalEnglish
Páginas (desde-hasta)505-515
Número de páginas11
PublicaciónBiological Research for Nursing
Volumen25
N.º4
DOI
EstadoPublished - oct 2023

Nota bibliográfica

Publisher Copyright:
© The Author(s) 2023.

Financiación

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by COVID-19 Basic, Translational and Clinical Research Fund from UC Irvine Office of the Vice Chancellor for Research and UL1TR001414–06 (NIH/NCATS).

FinanciadoresNúmero del financiador
UC Irvine Office of the Vice Chancellor for ResearchUL1TR001414–06
National Institutes of Health (NIH)
National Center for Advancing Translational Sciences (NCATS)

    ODS de las Naciones Unidas

    Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible

    1. Good health and well being
      Good health and well being

    ASJC Scopus subject areas

    • Research and Theory

    Huella

    Profundice en los temas de investigación de 'SARS-Cov-2 Infection and Seroconversion Rates in Healthcare Providers Prior to COVID-19 Vaccine Rollout'. En conjunto forman una huella única.

    Citar esto